Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) reported positive Phase 1 trial results for its drug candidate MRT-8102, which showed significant reductions in systemic and cardiovascular inflammatory biomarkers among high-risk participants. The GFORCE-1 study demonstrated an 80% to 90% median reduction in NEK7 degradation and substantial decreases in inflammation indicators, including an 85% reduction in hsCRP. Following these results, the company plans to initiate three Phase 2 studies, with the first expected to start in late 2026 or early 2027. At the time of publication, Monte Rosa's shares were down 6.41% to $11.17.